EMEA-003613-PIP01-24 - paediatric investigation plan
Ifinatamab deruxtecan
PIPHuman
Key facts
- Active Substance
- Ifinatamab deruxtecan
- Therapeutic area
- Neoplasms benign, malignant and unspecified (incl cysts and polyps)
- Decision number
- P/0250/2024
- PIP number
- EMEA-003613-PIP01-24
- Pharmaceutical form(s)
- All pharmaceutical forms
- Condition(s) / indication(s)
- Treatment of lung cancer (small cell and non-small cell lung cancer)
- Route(s) of administration
- All routes of administration
- Contact for public enquiries
Daiichi Sankyo Europe GmbH
E-mail: service@daiichi-sankyo.eu
Tel.: +49 8978080- Decision type
- W: decision granting a waiver in all age groups for all conditions or indications
- Decision date